Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT06556368 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

A Study to Evaluate the Efficacy and Safety of Tarcocimab Tedromer and Tabirafusp Tedromer Compared to Aflibercept in Participants With Neovascular (Wet) Age-related Macular Degeneration (wAMD) - DAYBREAK

Study acronym: DAYBREAK
StatusActive, Not Recruiting
PhasePhase 3
Started
View on ClinicalTrials.gov ↗
Record status
This record was last updated April 29, 2026 (before its estimated August 2026 completion). Its status may not reflect the trial's current state.

Record History

See every version on ClinicalTrials.gov ↗

  1. Site details revised at 1 of 72 sitesv10
  2. Primary endpoint revisedv9 Show 4 more changesShow less
    • Trial status: Recruiting to Active, Not Recruiting
    • Study sites: 78 to 72
    • Primary completion date: Apr 2026 to Aug 2026
    • Study completion date: Apr 2027 to Aug 2027
  3. Study sites: 76 to 78v8
  4. Study sites: 74 to 76v7
  5. Study sites: 69 to 74v6
Show 4 earlier versionsHide 4 earlier versions
  1. Study sites: 65 to 69
    • Primary completion date: Jan 2026 to Apr 2026
    • Study completion date: Jan 2026 to Apr 2027
    v5
  2. Study sites: 45 to 65v4
  3. Study sites: 23 to 45v3
  4. Study sites: 3 to 23
    • Start date changed from estimate of Aug 2024 to Aug 23, 2024
    v2
  1. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
A Study to Evaluate the Efficacy and Safety of Tarcocimab Tedromer and Tabirafusp Tedromer Compared to Aflibercept in Participants with Neovascular (Wet) Age-related Macular Degeneration (wAMD)
Trial Details
NCT Number NCT06556368
Lead Sponsor Kodiak Sciences Inc
Conditions
(from sponsor)		 Wet Age-related Macular Degeneration
Enrollment 675 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov